152 related articles for article (PubMed ID: 15660744)
1. Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone.
Shimizu H; Monden T; Nagai T; Shoda Y; Sato T; Yamada M; Mori M
Diabet Med; 2005 Feb; 22(2):225-6. PubMed ID: 15660744
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
4. [Glimepiride in daily practice].
Jasik M
Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
[TBL] [Abstract][Full Text] [Related]
5. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.
Forst T; Lübben G; Hohberg C; Kann P; Sachara C; Gottschall V; Friedrich C; Rosskopf R; Pfützner A
Microcirculation; 2005; 12(7):543-50. PubMed ID: 16207627
[TBL] [Abstract][Full Text] [Related]
6. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
Tattersall RB
Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
[No Abstract] [Full Text] [Related]
7. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
[TBL] [Abstract][Full Text] [Related]
8. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
9. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
10. Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.
Katakami N; Kaneto H; Matsuhisa M; Shimomura I; Yamasaki Y
Diabetes Res Clin Pract; 2011 Apr; 92(1):e20-2. PubMed ID: 21257219
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
13. [Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes].
Toyota T
Nihon Rinsho; 1999 Mar; 57(3):695-701. PubMed ID: 10199156
[TBL] [Abstract][Full Text] [Related]
14. [Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus].
Tang JZ; Mao JP; Yang ZF; Zhou ZG; Tang WL; Feng Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):631-4. PubMed ID: 16114544
[TBL] [Abstract][Full Text] [Related]
15. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
16. [Role of oral hypoglycemic agents in the therapeutic approach to diabetic obesity].
Albert J; Ekoé JM
Sem Hop; 1983 Sep; 59(29-30):2135-40. PubMed ID: 6312587
[TBL] [Abstract][Full Text] [Related]
17. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
[No Abstract] [Full Text] [Related]
18. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
[TBL] [Abstract][Full Text] [Related]
19. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
20. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
Anwar A; Azmi KN; Hamidon BB; Khalid BA
Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]